![]() Insilico used generative AI for each step of the preclinical drug discovery process: to identify a molecule that a drug compound could target, generate novel drug candidates, gauge how well these candidates would bind with the target, and even predict the outcome of clinical trials.ĭoing this using traditional methods would have cost more than $400 million and taken up to six years. The company’s early bet on deep learning is bearing fruit - a drug candidate discovered using its AI platform is now entering Phase 2 clinical trials to treat idiopathic pulmonary fibrosis, a relatively rare respiratory disease that causes progressive decline in lung function. While generative AI is a relatively new household term, drug discovery company Insilico Medicine has been using it for years to develop new therapies for debilitating diseases. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |